Wen-Wei Zhang

Wen-Wei Zhang

Auto-generated profile, based on publicly available information

Wen-Wei Zhang

Department of Microbiology and Immunology, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in mBio
Verified
Journal Article
Open access
PDF file
WZWen-Wei Zhang
Wen-Wei Zhang
GMGreg Matlashewski
Greg Matlashewski
The prokaryotic CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9, an RNA-guided endonuclease, has been shown to mediate efficient genome editing in a wide variety of organisms. In the present study, the CRISPR-Cas9 system has been adapted to Leishmania donovani , a protozoan parasite that causes fatal human visceral leishmaniasis. We introduced the Cas9 nuclease into L. donovani and generated guide RNA (gRNA) expression vectors by using the L. donovani rRNA promoter and the hepatitis delta virus (HDV) ribozyme. It is demonstrated within that L. donovani mainly used homology-directed repair (HDR) and microhomology-mediated end joining (MMEJ) to repair the Cas9 nuclease-created double-strand DNA break (DSB). The nonhomologous end-joining (NHEJ) pathway appears to be absent in L. donovani . With this CRISPR-Cas9 system, it was possible to generate knockouts without selection by insertion of an oligonucleotide donor with stop codons and 25-nucleotide homology arms into the Cas9 cleavage site. Likewise, we disrupted and precisely tagged endogenous genes by inserting a bleomycin drug selection marker and GFP gene into the Cas9 cleavage site. With the use of Hammerhead and HDV ribozymes, a double-gRNA expression vector that further improved gene-targeting efficiency was developed, and it was used to make precise deletion of the 3-kb miltefosine transporter gene ( LdMT ). In addition, this study identified a novel single point mutation caused by CRISPR-Cas9 in LdMT (M381T) that led to miltefosine resistance, a concern for the only available oral antileishmanial drug. Together, these results demonstrate that the CRISPR-Cas9 system represents an effective genome engineering tool for L. donovani. IMPORTANCE Leishmania donovani is the causative agent of fatal visceral leishmaniasis. To understand Leishmania infection and pathogenesis and identify new drug targets for control of leishmaniasis, more-efficient ways to manipulate this parasite genome are required. In this study, we have implemented CRISPR-Cas9 genome-editing technology in L. donovani . Both single- and dual-gRNA expression vectors were developed using a strong RNA polymerase I promoter and ribozymes. With this system, it was possible to generate loss-of-function insertion and deletion mutations and introduce drug selection markers and the GFP sequence precisely into the L. donovani genome. These methods greatly improved the ability to manipulate this parasite genome and will help pave the way for high-throughput functional analysis of Leishmania genes. This study further revealed that double-stranded DNA breaks created by CRISPR-Cas9 were repaired by the homology-directed repair (HDR) pathway and microhomology-mediated end joining (MMEJ) in Leishmania .

1 October 2001 in Vaccine
Verified
Journal Article
Closed access
AGAnirban Ghosh
Anirban Ghosh
WZWen Wei Zhang
Wen Wei Zhang
GMGreg Matlashewski
Greg Matlashewski

5 August 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WZWen-Wei Zhang
Wen-Wei Zhang
GMGreg Matlashewski
Greg Matlashewski
Leishmania donovaniis the etiologic agent of fatal visceral leishmaniasis in man. During their life cycle,Leishmaniaexist as flagellated promastigotes within the sandfly vector and as nonflagellated amastigotes in the macrophage phagolysosomal compartment of the mammalian host. The transformation from promastigotes to amastigotes is a critical step for the establishment of infection, and the molecular basis for this transformation is poorly understood. To define the molecular basis for amastigote survival in the mammalian host, we previously identified an amastigote stage-specific gene family termed “A2.” In the present study, we have inhibited the expression of A2 mRNA and A2 protein in amastigotes using antisense RNA and show that the resulting A2-deficient amastigotes are severely compromised with respect to virulence in mice. Amastigotes that did survive in the mice had restored A2 protein expression. These data demonstrate that A2 protein is required forL. donovanisurvival in a mammalian host, and this represents the first identified amastigote-specific virulence factor identified inLeishmania. This study also reveals that it is possible to study gene function inLeishmaniathrough the expression of antisense RNA.

1 June 1996 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
WZWen-Wei Zhang
Wen-Wei Zhang
HCHugues Charest
Hugues Charest
EGElodie Ghedin
Elodie Ghedin
GMGreg Matlashewski
Greg Matlashewski

1 February 2001 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
WZWen‐Wei Zhang
Wen‐Wei Zhang
GMGreg Matlashewski
Greg Matlashewski
The A2 gene family is present in Leishmania donovani, which causes fatal visceral leishmaniasis in human patients, but is not present in Leishmania major, which causes cutaneous leishmaniasis infections. The A2 genes in L. donovani are stage specific and are expressed at high levels in the amastigote stage in the mammalian host, but are not expressed in the promastigote stage in the insect sandfly vector. The A2 genes are tandem repeated with a distinct gene family termed the A2rel genes. In order to characterize the structure and function of the A2–A2rel gene clusters, the 5′ and 3′ DNA sequences flanking the A2–A2rel cluster were isolated, sequenced and used to generate mutants through gene targeting. Although it was possible to generate partial A2–A2rel gene clusters knock‐out mutants, it was not possible to delete all the A2–A2rel gene clusters completely from the L. donovani genome, suggesting that, within this cluster, there are genes that are essential for survival in culture. Characterization of these mutants revealed that A2 and A2rel gene expression was compensated by amplifying the remaining intact A2 and A2rel genes, and the proliferation of these mutants in culture and their virulence in BALB/c mice were compromised. In order to explore further the biological role of A2, the L. donovani A2 gene was introduced into L. major. In comparison with the control L. major, the A2‐expressing L. major parasites demonstrated an increased ability to survive in the spleen of BALB/c mice. These data suggest that A2 plays a role in the visceralization of infection associated with L. donovani.

10 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWen-Wei Zhang
Wen-Wei Zhang
SKSubir Karmakar
Subir Karmakar
SGSreenivas Gannavarram
Sreenivas Gannavarram
RDRanadhir Dey
Ranadhir Dey
PLPatrick Lypaczewski
Patrick Lypaczewski
HNHira L Nakhasi
Hira L Nakhasi
Leishmaniasis is a neglected tropical disease caused by Leishmania protozoa transmitted by infected sand flies. Vaccination through leishmanization with live Leishmania major has been used successfully but is no longer practiced because it resulted in occasional skin lesions. A second generation leishmanization is described here using a CRISPR genome edited L. major strain (LmCen−/−). Notably, LmCen−/− is a genetically engineered centrin gene knock-out mutant strain that is antibiotic resistant marker free and does not have detectable off-target mutations. Mice immunized with LmCen−/− have no visible lesions following challenge with L. major-infected sand flies, while non-immunized animals develop large and progressive lesions with a 2-log fold higher parasite burden. LmCen−/− immunization results in protection and an immune response comparable to leishmanization. LmCen−/− is safe since it is unable to cause disease in immunocompromised mice, induces robust host protection against vector sand fly challenge and because it is marker free, can be advanced to human vaccine trials.